THERAPY DOSSIER · th-d22a96cce2f3

rHA-Infestin-4 (recombinant human albumin-fused infestin-4), a selective inhibitor of activated factor XII

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27043916 ↗2016Reported benefit

Targeting coagulation factor XII as a novel therapeutic option in brain trauma.

MouseTBIWeight-drop / impact-accelerationC57BL/6N wild-type, FXII-deficient and FXI-deficient miceMale and femalen = 148 C57BL/6N wild-type mice (134 male, 14 female), 60 FXII-…Intravenous200 mg/kg body weightSingle bolus after injury induction; reconstitution experiments with human FXII…

Model: Weight-drop closed-head injury (concussion-like diffuse TBI) and cortical cryolesion

Both genetic factor XII deficiency and pharmacological inhibition of activated factor XII with rHA-Infestin-4 minimised trauma-induced microvascular thrombus formation and improved outcome, with better motor function, reduced brain lesion volume and diminished neurodegeneration, without increasing…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…